Perioperative systemic therapy in renal cell carcinoma

被引：0
|
作者：
Macphail, Ceilidh [1 ]
Wood, Lori A. [1 ]
Thana, Myuran [1 ]
机构：
[1] Dalhousie Univ, Div Med Oncol, Halifax, NS, Canada
来源：
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE | 2023年 / 17卷 / 04期
关键词：
adjuvant immunotherapy; perioperative immune checkpoint inhibitor; renal cell carcinoma; DISEASE-FREE SURVIVAL; UPDATED EUROPEAN ASSOCIATION; HIGH-RISK; ADJUVANT SUNITINIB; RADICAL NEPHRECTOMY; UROLOGY GUIDELINES; DOUBLE-BLIND; END-POINT; PLACEBO; CANCER;
D O I：
10.1097/SPC.0000000000000675
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Purpose of review Renal cell carcinoma (RCC) is the most common kidney neoplasm. Localized RCC can be cured with nephrectomy. However, a proportion of patients will recur with incurable distant metastatic disease. There is a clear need for treatments to reduce the risk of RCC recurrence and thus improve survival. This review describes the landscape of perioperative therapy for RCC, focusing on more recent trials involving immune checkpoint inhibitors (ICIs). Recent findings ICIs have significantly changed outcomes in advanced RCC. Four trials investigating the role of perioperative ICI for RCC are now reported. Only one trial utilizing adjuvant pembrolizumab (Keynote-564) has shown a disease-free survival benefit in resected RCC. Summary Patients with resected RCC should be counselled on their risk of recurrence and the potential option of adjuvant pembrolizumab, recognizing that overall survival data are not yet available.
引用
收藏
页码：301 / 307
页数：7
相关论文
共 50 条
  • [21] Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Chanza, Nieves Martinez
    Tripathi, Abhishek
    Harshman, Lauren C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (05)
  • [22] Combination Systemic Therapy for Advanced Renal Cell Carcinoma
    Miller, Rowan E.
    Larkin, James M. G.
    ONCOLOGIST, 2009, 14 (12) : 1218 - 1224
  • [23] Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out
    Esteban-Villarrubia, Jorge
    Ferreiro, Carmen Romero
    Carril-Ajuria, Lucia
    Carretero-Gonzalez, Alberto
    Iacovelli, Roberto
    Albiges, Laurence
    Castellano, Daniel
    de Velasco, Guillermo
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (09) : 391.e13 - 391.e21
  • [24] Is there a role for presurgical therapy for renal cell carcinoma?
    Calabro, Fabio
    Sternberg, Cora N.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (06) : 807 - 812
  • [25] Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
    Larroquette, Mathieu
    Peyraud, Florent
    Domblides, Charlotte
    Lefort, Felix
    Bernhard, Jean-Christophe
    Ravaud, Alain
    Gross-Goupil, Marine
    CANCER TREATMENT REVIEWS, 2021, 97
  • [26] Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma
    de Velasco, Guillermo
    Bex, Axel
    Albiges, Laurence
    Powles, Thomas
    Rini, Brian I.
    Motzer, Robert J.
    Heng, Daniel Y. C.
    Escudier, Bernard
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (05): : 505 - 514
  • [27] Systemic therapy for sarcomatoid renal cell carcinoma
    Pagliaro, Lance C.
    Tannir, Nizar
    Sircar, Kanishka
    Jonasch, Eric
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (06) : 913 - 920
  • [28] Systemic therapy of metastatic renal cell carcinoma
    Autenrieth, M.
    Heidenreich, A.
    Gschwend, J. E.
    UROLOGE, 2006, 45 (05): : 594 - 599
  • [29] Systemic therapy in metastatic renal cell carcinoma
    Jens Bedke
    Thomas Gauler
    Viktor Grünwald
    Axel Hegele
    Edwin Herrmann
    Stefan Hinz
    Jan Janssen
    Stephan Schmitz
    Martin Schostak
    Hans Tesch
    Stefan Zastrow
    Kurt Miller
    World Journal of Urology, 2017, 35 : 179 - 188
  • [30] Promising systemic therapy for renal cell carcinoma
    Cooney M.M.
    Remick S.C.
    Vogelzang N.J.
    Current Treatment Options in Oncology, 2005, 6 (5) : 357 - 365
12345